JonesTrading analyst Soumit Roy maintained a Buy rating on HCW Biologics (HCWB – Research Report) today and set a price target of $8.00. The company’s shares opened today at $1.52.
Roy covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Monopar Therapeutics Inc, and Rain Therapeutics. According to TipRanks, Roy has an average return of 0.0% and a 28.44% success rate on recommended stocks.
Currently, the analyst consensus on HCW Biologics is a Moderate Buy with an average price target of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on HCW Biologics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.81 million and a GAAP net loss of $3.91 million. In comparison, last year the company had a GAAP net loss of $4.09 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HCW Biologics Inc is a preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. It is developing HCW9218 as an injectable immunotherapeutic for patients with solid tumors.
Read More on HCWB:
